Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07050173
PHASE1

Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation

Sponsor: Pravat Mandal

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to test whether the gamma - glutamylcystiene (GGC) oral supplement can reach the brain and subsequently increase antioxidant glutathione (GSH) level in people with repetitive head impact (RHI). This will reduce the oxidative stress related injury in people with RHI.This unique study's main objective is to test the: 1. Change in GSH in brain and blood levels through GGC supplementation. 2. Change in the cognitive function in RHI patients due to GGC supplementation.

Official title: Patients With Repetitive Head Impact Orally Supplemented With Gamma-glutamylcysteine: An Open Label Trial With MR Spectroscopy and Neuropsychological Testing

Key Details

Gender

All

Age Range

30 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2026-04

Completion Date

2027-12-27

Last Updated

2026-04-09

Healthy Volunteers

No

Interventions

DRUG

Gamma-glutamylcysteine (GGC)

400mg tablet orally (two times) per day.

Locations (1)

UPMC Presbyterian Hospital

Pittsburgh, Pennsylvania, United States